Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction

Tuca, 2012, Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution, Cancer Manag Res, 4, 159, 10.2147/CMAR.S29297

Mercadante, 1993, Octreotide in relieving gastrointestinal symptoms due to bowel obstruction, Palliat Med, 7, 295, 10.1177/026921639300700406

Henry, 2012, A scoring system for the prognosis and treatment of malignant bowel obstruction, Surgery, 152, 747, 10.1016/j.surg.2012.07.009

Kucukmetin, 2010, Palliative surgery versus medical management for bowel obstruction in ovarian cancer, Cochrane Database Syst Rev, CD007792

Feuer, 2000, Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer, Cochrane Database Syst Rev, CD002764

Feuer, 2000, Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer, Cochrane Database Syst Rev, CD001219

Murakami, 2013, Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction, Anticancer Res, 33, 5557

Clark, 2009, Reducing gastric secretions—a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?, Support Care Cancer, 17, 1463, 10.1007/s00520-009-0609-3

Gyr, 1992, Pharmacodynamic effects of Sandostatin in the gastrointestinal tract, Metabolism, 41, 17, 10.1016/0026-0495(92)90026-7

Mariani, 2012, Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study, J Clin Oncol, 30, 4337, 10.1200/JCO.2011.40.5712

Laval, 2012, SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction, Bull Cancer, 99, E1, 10.1684/bdc.2011.1535

Mercadante, 2000, Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction, Support Care Cancer, 8, 188, 10.1007/s005200050283

Ripamonti, 2000, Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial, J Pain Symptom Manage, 19, 23, 10.1016/S0885-3924(99)00147-5

Mystakidou, 2002, Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial, Anticancer Res, 22, 1187

Kubota, 2013, Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer, Asian Pac J Cancer Prev, 14, 7107, 10.7314/APJCP.2013.14.12.7107

Watari, 2012, A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer, Int J Gynecol Cancer, 22, 692, 10.1097/IGC.0b013e318244ce93

Bellavance, 2012, Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction, J Clin Oncol, 30, 4290, 10.1200/JCO.2012.45.0536

Vervoort, 2002, Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation, Nephrol Dial Transplant, 17, 1909, 10.1093/ndt/17.11.1909

Ripamonti, 2008, Management of malignant bowel obstruction, Eur J Cancer, 44, 1105, 10.1016/j.ejca.2008.02.028

Steiner, 1998, Methods of hydration in palliative care patients, J Palliat Care, 14, 6, 10.1177/082585979801400202

Nakajima, 2013, A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies, J Palliat Med, 16, 185, 10.1089/jpm.2012.0233

Olver, 1994, The roles of patient and observer assessments in anti-emetic trials, Eur J Cancer, 30, 1223, 10.1016/0959-8049(94)90162-7

Farrar, 2001, Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale, Pain, 94, 149, 10.1016/S0304-3959(01)00349-9

National Cancer Institute. Cancer therapy evaluation program. Common terminology for adverse events V3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm. Accessed April 10, 2013.

Cleeland, 1994, Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, 23, 129

Abernethy, 2005, The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481], BMC Palliat Care, 4, 7, 10.1186/1472-684X-4-7

Saxby, 2007, How should we measure emesis in palliative care?, Palliat Med, 21, 369, 10.1177/0269216307080173

Guyatt, 2002, Methods to explain the clinical significance of health status measures, Mayo Clin Proc, 77, 371, 10.4065/77.4.371

Schafer, 1999, Multiple imputation: a primer, Stat Methods Med Res, 8, 3, 10.1191/096228099671525676

Londong, 1989, Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration, Gastroenterology, 96, 713, 10.1016/S0016-5085(89)80069-1

Hisanaga, 2010, Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction, Jpn J Clin Oncol, 40, 739, 10.1093/jjco/hyq048

Sanderson, 2013, Placebo and nocebo effects in randomized controlled trials: the implications for research and practice, J Pain Symptom Manage, 46, 722, 10.1016/j.jpainsymman.2012.12.005

Kunz, 1998, The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials, BMJ, 17, 1185, 10.1136/bmj.317.7167.1185

Stinnett, 1998, Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis, Med Decis Making, 18, S68, 10.1177/0272989X98018002S09